OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Subscribe To Our Newsletter & Stay Updated
